AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Biology of aging and tips to slow it down | Matt Kaeberlein, PhD
The Proof with Simon Hill
Is FDA Approval for Aging Going to Be an Important Piece of the Puzzle?
4min Snip
00:00
Summary
Transcript
Episode notes
Rapamycin doesn't have to be approved by FDA for anything more at this point because it's already approved. So I think there's a lot of misunderstanding around what FDA is looking for when we're talking about drugs that target the biology of aging. We need quantitative endpoints that either are surrogates for biological aging, and that's where these clocks may come in. There's really nothing saying you couldn't do a clinical trial showing that you can improve muscle function in the elderly and not get a drug approved for that.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode